Status:
RECRUITING
International Multisite Transcatheter Tricuspid Valve Therapies Registry
Lead Sponsor:
University of Zurich
Conditions:
Severe Tricuspid Regurgitation
Eligibility:
All Genders
18-99 years
Brief Summary
For a long time, tricuspid valve disease has been considered as less important than left-sided valvular heart disease. If treated in an advanced stage and simultaneously with other cardiac diseases, i...
Eligibility Criteria
Inclusion
- All the patients undergoing transcatheter tricuspid valve intervention.
- General inclusion criteria:
- Minimal age: 18 years
- Patient is able to give written informed consent to the procedure
Exclusion
- Patients not fulfilling the indications for transcatheter tricuspid intervention
Key Trial Info
Start Date :
November 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2026
Estimated Enrollment :
269 Patients enrolled
Trial Details
Trial ID
NCT03416166
Start Date
November 1 2016
End Date
November 1 2026
Last Update
January 30 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Zurich
Zurich, Switzerland